Stock Market Reviews

NEO (NeoGenomics, Inc.) News

Get the latest news, insights, and market updates on NEO (NeoGenomics, Inc.). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• NeoGenomics Appoints Diagnostics and Lab Services Industry Veteran John P. "Jack" Kenny to its Board of Directors
  FORT MYERS, Fla., December 30, 2025--NeoGenomics announced the appointment of John P. "Jack" Kenny to its Board of Directors.
  Dec 30, 2025 - $NEO
• 3 Russell 2000 Stocks We Think Twice About
  Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resources than their bigger counterparts, these companies face steeper challenges in scaling their businesses.
  Dec 18, 2025 - $NEO
• 3 Stocks Under $50 We Steer Clear Of
  The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.
  Dec 17, 2025 - $NEO
• NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litigation
  FORT MYERS, Fla., December 15, 2025--NeoGenomics announced that Natera has voluntarily withdrawn its appeal in ongoing RaDaR patent litigation.
  Dec 15, 2025 - $NEO
• NeoGenomics (NEO): Assessing Valuation After a 44% Three-Month Share Price Rebound
  NeoGenomics (NEO) has quietly strung together a solid rebound, with shares up roughly 44% over the past 3 months and about 16% this month, drawing fresh attention after a tough year. See our latest analysis for NeoGenomics. Despite that sharp 90 day share price return, NeoGenomics is still nursing a negative year to date share price return and a weak one year total shareholder return. This suggests momentum is rebuilding from a low base as investors reassess its growth prospects. If...
  Dec 11, 2025 - $NEO
• NeoGenomics to Present New ctDNA Research at SABCS 2025
  FORT MYERS, Fla., December 10, 2025--NeoGenomics will present data on its RaDaR 1.0 assay for molecular residual disease detection at the 2025 San Antonio Breast Cancer Symposium.
  Dec 10, 2025 - $NEO
• NeoGenomics to Present Real-World Study on Comprehensive Genomic Profiling in Myeloid Malignancies at ASH 2025
  FORT MYERS, Fla., December 08, 2025--NeoGenomics will present new data at ASH on how comprehensive genomic profiling supports diagnosis and treatment decisions in myeloid malignancies.
  Dec 8, 2025 - $NEO
• Testing & Diagnostics Services Stocks Q3 Recap: Benchmarking NeoGenomics (NASDAQ:NEO)
  The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how NeoGenomics (NASDAQ:NEO) and the rest of the testing & diagnostics services stocks fared in Q3.
  Dec 5, 2025 - $NEO
• 3 Overrated Stocks That Concern Us
  The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro developments. As such, investors are taking notice and bidding up shares.
  Dec 4, 2025 - $NEO
• 1 Cash-Burning Stock to Research Further and 2 We Brush Off
  Rapid spending isn’t always a sign of progress. Some cash-burning businesses fail to convert investments into meaningful competitive advantages, leaving them vulnerable.
  Nov 25, 2025 - $NEO